Last updated: February 15, 2026
What is NDC 00078-0778?
NDC 00078-0778 corresponds to Mitomycin injection, a chemotherapy agent used primarily in the treatment of various cancers including gastric, colorectal, and pancreatic cancers. It is administered intravenously under oncologist supervision.
Market Size and Demand
Global and U.S. Market
- The global oncology drug market was valued at approximately $176 billion in 2021, with chemotherapy agents comprising about 45% of this figure[^1].
- Mitomycin is a niche among top-selling chemotherapies, but its demand fluctuates based on prevalence, clinical guidelines, and approval status.
- In the U.S., estimated annual prescriptions for mitomycin have ranged between 10,000 and 15,000 units in recent years; this is based on Centers for Medicare & Medicaid Services (CMS) and IQVIA data[^2].
Key Factors Influencing Demand
- Increasing prevalence of cancers treatable with mitomycin.
- Changes in clinical practice guidelines favoring or limiting use.
- Competitive landscape and alternative therapies including newer biologics or targeted agents.
Competitive Landscape
Major Market Players
- Pfizer and Teva manufacture branded and generic formulations.
- Several smaller companies produce bioequivalent generics.
- Patent expiration for earlier formulations has increased generic penetration.
Pricing and Reimbursement
- Average wholesale price (AWP): Approximately $250 - $350 per vial, depending on the supplier and volume.
- Reimbursement rates align with this, though actual net prices to hospitals and clinics are lower due to negotiations and discounts.
Regulatory and Patent Considerations
- No active patents for mitomycin formulations remain in the U.S.
- FDA approvals are stable, though new indications or formulations require supplemental filings.
- Recent regulatory filings focus on biosimilar development, which could impact pricing and market share.
Price Projections (Next 3-5 Years)
| Year |
Estimated Average Price per Vial |
Comments |
| 2023 |
$250 - $350 |
Current levels; generic formulations expanding |
| 2024-2025 |
Slight decline to $230 - $330 |
Due to increased generic competition; potential biosimilar entries |
| 2026-2027 |
Stabilization at $220 - $310 |
Market saturation; price sensitivity; hospital negotiations |
Assumptions
- No new patent protections or exclusive marketing rights.
- Competitive generic entry intensifies.
- Continued availability of biosimilars or alternatives.
Key Drivers and Risks
Drivers
- Rising cancer incidence rates worldwide.
- Expanding approval for combination therapies.
- Cost containment efforts favoring generic use.
Risks
- Introduction of new targeted therapies or immunotherapies reducing mitomycin’s role.
- Regulatory changes limiting off-label or routine use.
- Supply chain disruptions influencing prices.
Key Takeaways
- The overall market for mitomycin injection remains modest, with U.S. prescriptions between 10,000 and 15,000 annually.
- Price levels are around $250-$350 per vial, with downward pressure expected due to increased generic competition.
- Market growth primarily depends on cancer prevalence, shifts in treatment paradigms, and biosimilar development.
- Price stability is unlikely in the absence of new patent protections or unique indications, with expected prices declining gradually over the next five years.
FAQs
1. What factors could significantly alter the price of NDC 00078-0778?
Introduction of biosimilars or new indications could lower prices. Conversely, supply shortages or regulatory restrictions might increase costs temporarily.
2. How does the approval status of biosimilars impact mitomycin pricing?
Biosimilar approvals can drive prices down by increasing competition, similar to generic drugs, especially if bioequivalent versions are approved for the same indications.
3. Are there key markets outside the U.S. where mitomycin demand is higher?
Emerging markets in Asia and Latin America have growing cancer treatment needs. However, pricing and access policies vary and influence market size.
4. How does insurance reimbursement impact the net price hospitals pay?
Reimbursement rates are negotiated, often lower than the AWP, reducing net prices paid by healthcare providers.
5. What are the main clinical considerations influencing mitomycin use?
Its toxicity profile, compatibility with combination regimens, and evolving evidence from clinical trials guide prescribing decisions.
Sources
- IQVIA, Global Oncology Market Report, 2022.
- Centers for Medicare & Medicaid Services (CMS), Prescription Data, 2022.
